
A&G Pharmaceutical Inc (AKA: A and G Pharmaceutical Inc) Profile last edited on: 9/21/2022
CAGE: 1T9L5
UEI: SN6SWFABJXL1
Business Identifier: Cancer therapeutics and diagnostics: theranostic products Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: Howard
Congr. District: 03
County: Howard
Public Profile
A&G Pharmaceutical, Inc. is organized around development to in-use conditon of theranostic products and drug/test combinations that enhance screening, detection, and treatment of cancer and other human diseases. The company primarily focuses on developing molecular tests that detect cancer at earlier stages when it is treatable and develops associated treatments that precisely target and destroy cancer. It offers GP88/progranulin, a biomarker produced by breast cancer tumors and used to help the cancer grow and proliferate. The company provides GP88-based breast cancer diagnostic test kits to enhance early detection, diagnosis, and treatment of breast cancer. It also focuses on developing anti-GP88 monoclonal antibody therapeutics; and screening for monoclonal antibodies that recognize ovarian, pancreatic, prostate, and lung cancer. The aim is to develop personalized approaches to treating cancer.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 2 | NIH | $2,048,419 | |
Project Title: Pharmacology & Human Phase 1 Safety & Dose Escalation Studies Using Anti-GP88 in Aggressive Breast Cancer | ||||
2022 | 2 | NIH | $1,466,417 | |
Project Title: A Circulating Biomarker for Use in Monitoring Metastatic Breast Cancer | ||||
2018 | 2 | NIH | $2,181,979 | |
Project Title: Targeted Therapy for Non Small Cell Lung Carcinoma: in Vivo Feasibility Studies | ||||
2014 | 2 | NIH | $1,677,932 | |
Project Title: Novel Agent to Restore Sensitivity to Anti-Estrogen Therapy | ||||
2013 | 1 | NIH | $199,828 | |
Project Title: Smart Fusion: High Affinity Peptide Capture Reagentspop: 0 |
Key People / Management
Ginette Serrero -- Co-Founder ; CEO
Randy Barton -- Vice President of Drug Discovery
Jun Hayashi -- Co-Founder and VP of Research and Development
David Hicks -- Director of Product Development
Michael Keefe -- COO
Gordon Sato -- Co-Founder
Le Sun -- former president
Randy Barton -- Vice President of Drug Discovery
Jun Hayashi -- Co-Founder and VP of Research and Development
David Hicks -- Director of Product Development
Michael Keefe -- COO
Gordon Sato -- Co-Founder
Le Sun -- former president